HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Almay

This article was originally published in The Rose Sheet

Executive Summary

Exec VP and General Manager Sharon LeVan responsible for Almay and Ultima II brand development is leaving post to start own company, Revlon says. She will be succeeded by Hillary Soloman, formerly VP-marketing, who has helped lead development of Almay's Milk Plus skin care line and organic nail treatment products launching in 2001 (1"The Rose Sheet" July 3, pp. 3-4)

You may also be interested in...



Almay Milk Plus Skin Care To Drink In $28 Mil. At Retail, Revlon Predicts

Almay will re-emphasize its skin care heritage with the December introduction of six-SKU Milk Plus, the Revlon company said. The line, introduced at the National Association of Chain Drug Stores Marketplace convention in New Orleans June 25-28, is expected to generate $28 mil. in retail consumption.

OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"

With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program

Beauty Claims Inch Closer To Pharma As Cosmeceutical Sector Expands

Though global market-size estimates differ, analysts at SupplySide West 2010 in Las Vegas agreed that cosmeceuticals remain a promising growth vehicle

Latest Headlines
See All
UsernamePublicRestriction

Register

RS008689

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel